Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tissue RepairASX:TRP Current Ratio is 6.36 as of Jun. 2026, which is 81% below its 10-year median of 34.37. The stock has 2 warning signs investors should review. Among 1,408 Biotechnology companies, Tissue Repair ranks better than 66.12% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Tissue Repair's current ratio for the quarter that ended in Jun. 2026 was 6.36.
Tissue Repair has a current ratio of 6.36. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Tissue Repair's Current Ratio or its related term are showing as below:
ASX:TRP'
s Current Ratio Range Over the Past 10 Years
Min: 6.36 Med: 34.37 Max: 73.59
Current: 6.36
During the past 6 years, Tissue Repair's highest Current Ratio was 73.59. The lowest was 6.36. And the median was 34.37.
ASX:TRP's Current Ratio is ranked better than 66.12% of 1408
companies
in the Biotechnology industry
Industry Median: 3.885
vs ASX:TRP: 6.36
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Tissue Repair Current Ratio Related Terms
Tissue Repair Current Ratio Historical Data
* Premium members only.
The historical data trend for Tissue Repair's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:TRP vs VRTX, REGN, MRNA: Current Ratio Comparison
For the Biotechnology subindustry, Tissue Repair's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tissue Repair Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tissue Repair's Current Ratio distribution charts can be found below:
* The bar in red indicates where Tissue Repair's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tissue Repair (ASX:TRP) has a Current Ratio of 6.36 as of Jun. 2026. This is 81% below median its historical median of 34.37. Over the past decade, Tissue Repair's Current Ratio has ranged from 6.36 to 73.59. According to the industry distribution chart, Tissue Repair ranks #477 out of 1408 companies in the Biotechnology industry, placing it in the top 33.9%.
Is Tissue Repair's Current Ratio too high?
Tissue Repair's current Current Ratio of 6.36 is 81% below median its 10-year median of 34.37. Over the past 10 years, this metric has ranged from a low of 6.36 to a high of 73.59. The Biotechnology industry median Current Ratio is 3.89. Tissue Repair's value of 6.36 is 63.7% above this industry median. Based on the distribution chart, Tissue Repair ranks #477 out of 1408 companies in the Biotechnology industry, which is above the industry midpoint.
How does Tissue Repair's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tissue Repair ranks #477 out of 1408 companies for Current Ratio. This puts Tissue Repair in the upper half of its industry. The industry median Current Ratio is 3.89. Tissue Repair's value of 6.36 is 63.7% above this benchmark. Historically, Tissue Repair's own Current Ratio has ranged from 6.36 to 73.59 over the past decade. While the company's 10-year median is 34.37 vs. the industry median of 3.89, Tissue Repair has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,408 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tissue Repair's current Current Ratio of 6.36 is 63.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tissue Repair's current Current Ratio is 6.36, which is 81% below median its own 10-year median of 34.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Repair stock overvalued right now?
Based on GuruFocus' analysis, Tissue Repair (ASX:TRP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.52, compared to a current price of A$0.08 — trading 84.6% below its estimated fair value. The current Current Ratio is 6.36, which is 81% below median its 10-year median of 34.37 and 63.7% above the Biotechnology industry median of 3.89. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Tissue Repair (ASX:TRP), the current Current Ratio is 6.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tissue Repair Ltd is a clinical-stage biopharmaceutical company engaged in development of wound healing products for chronic wounds and the aftercare of cosmetic procedures, with the potential for further development of related technologies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TRP has been successfully added to your 
